InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,513.20
(
0.37%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.45
(
0.44%
)
Bitcoin
68,806.68
(
1.46%
)
Post# of 253527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120665
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: staccani post# 207507

Friday, 07/07/2017 4:32:57 PM

Friday, July 07, 2017 4:32:57 PM

Post# of 253527
ITEK -45%/AH on phase-2 failure:

https://www.businesswire.com/news/home/20170707005601/en

“While the top-line results, which we received and analyzed over the past week, demonstrated a good safety and tolerability profile of the fixed-dose combinations of trabodenoson and latanoprost, the efficacy of the FDC was only marginally differentiated from that of latanoprost alone. Based on these results and the results previously reported for our Phase 3 MATrX-1 monotherapy trial, we are evaluating the future clinical potential of trabodenoson, as well as other strategic options.”

CC Monday at 8:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up